Brain training without drugs: new hope for ADHD teens?

NCT ID NCT07285681

Ongoing Symptom relief Sponsor: Tanta University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether neurofeedback—a non-invasive brain training technique—can reduce symptoms of attention deficit hyperactivity disorder (ADHD) in teenagers. Researchers in Tanta, Egypt, are enrolling 40 participants aged 12 to 18. The approach uses real-time brain activity feedback to help teens learn to self-regulate their focus and behavior, aiming to improve attention and reduce hyperactivity without medication.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Neurofeedback (a brain-training device that uses EEG to teach self-regulation of brain activity)
What this could lead to: If it works, this could offer a non-drug option for managing ADHD symptoms in teenagers, potentially reducing reliance on medication.
What could go wrong: This is a small, early-stage study with only 40 participants and no control group, so results may not be widely applicable. The benefits may also fade after treatment ends.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY (ADHD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

attention deficit hyperactivity disorder, inattentive type attention deficit-hyperactivity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY (ADHD)

Contacts and locations

Locations

NeuroPsychiatry Department - Faculty of Medicine - Tanta University

Tanta, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.